Assessment of the Clinical and Economic Impact of Different Immunization Protocols of Measles, Mumps, Rubella and Varicella in Internationally Adopted Children

Sara Boccalini 1,*, Angela Bechini 1, Cecilia Maria Alimenti 1, Paolo Bonanni 1, Luisa Galli 1,2 and Elena Chiappini 1,2

1 Department of Health Sciences, University of Florence, Viale GB Morgagni, 48 – 50134 Florence, Italy; sara.boccalini@unifi.it (S.B.); angela.bechini@unifi.it (A.B.); cecilia.alimenti@stud.unifi.it (C.M.A.); paolo.bonanni@unifi.it (P.B.);
2 Meyer Children’s University Hospital, Viale Pieraccini 24 – 50139 Florence, Italy; luisa.galli@unifi.it (L.G.); elena.chiappini@unifi.it (E.C.).

* Correspondence: sara.boccalini@unifi.it; Tel.: +39-055-2751084

Received: 23 December 2019; Accepted: 30 January 2020; Published: 1 February 2020

Abstract: The appropriate immunization of internationally adopted children (IAC) is currently under debate and different approaches have been suggested. The aim of this study is to evaluate the clinical and economic impact of different strategies of measles, mumps, rubella, and varicella (MMRV) immunization in IAC in Italy. A decision analysis model was developed to compare three strategies: presumptive immunization, pre-vaccination serotesting and vaccination based on documentation of previous immunization. Main outcomes were the cost of strategy, number of protected IAC, and cost per child protected against MMRV. Moreover, the incremental cost-effectiveness ratio (ICER) was calculated. The strategy currently recommended in Italy (immunize based on documentation) is less expensive. On the other hand, the pre-vaccination serotesting strategy against MMRV together, improves outcomes with a minimum cost increase, compared with the presumptive immunization strategy and compared with the comparator strategy. From a cost-effectiveness point of view, vaccination based on serotesting results in being the most advantageous strategy compared to presumptive vaccination. By applying a chemiluminescent immunoassay test, the serology strategy resulted to be clinically and economically advantageous. Similar results were obtained excluding children aged <1 year for both serology methods. In conclusion, based on our analyses, considering MMRV vaccine, serotesting strategy appears to be the preferred option in IAC.

Keywords: Internationally adopted children; vaccination; vaccine preventable diseases; children; adoptees; measles; mumps; rubella; varicella; infectious diseases

1. Introduction

Appropriate immunization of internationally adopted children (IAC) is currently under debate and different approaches have been suggested [1]. In the literature, three possible approaches to vaccinate IAC have been described [1,2].

The first approach is to assess and accept reliable documentation of previous vaccinations and then immunize the child, following the local schedule [3]. In order to assess the reliability of vaccine documentation, physicians should evaluate the dates of vaccine administration, the number of doses
administered, intervals between doses, and the IAC age at the time of administration. This is the strategy recommended in Italy.

The second approach is to test specific antibody titers. Children should be immunised if no protective antibody titers are found. On the other hand, if protective antibody levels are detected, IAC should be provided with vaccinations according to their age and the national schedule [4]. Testing antibody titers could be carried out for many vaccine preventable diseases (VPDs). However, the performance of serologic tests varies according to the considered VPDs. Limited data suggest that this strategy could be cost-effective for older children [5]. This approach reduces the number of unnecessary injections. [6].

The third approach is to re-immunise all IAC without considering their vaccination records, as there is no evidence of adverse events from extra doses of most vaccines [7].

It is not currently known which of these three options provides the most cost-effective approach.

Previous studies found different results depending on the VPDs and the prevalence of the disease in the population [8–11]. Serology for varicella in refugees older than five years of age was observed to be cost-effective in one study of 637 children [8]. On the other hand, presumptive vaccination was found to be cost-effective for HBV and HAV in two studies when the prevalence was >40% and >22%, respectively [9,10].

A previous economic analysis compared pre-vaccination serotesting and presumptive immunization for poliomyelitis, diphtheria, and tetanus in IAC. The authors concluded that appropriate immunization of IAC is currently under debate and different approaches have been suggested, presumptive immunization for the poliovirus improved outcomes and saved costs compared with serotesting. However, the results for tetanus and diphtheria were less definitive and were influenced by the assumed seroprevalence and compliance to the three-dose-vaccination schedule [11]. To our knowledge, no previous study has investigated the preferred strategy in IAC relative to measles mumps rubella varicella (MMRV) vaccination.

MMRV are highly communicable infectious diseases. Due to inadequate immunization coverage outbreaks of measles and other VPDs have been reported worldwide in recent years among the general population [12].

In total, 13,460 cases of measles have been reported in adults and children by the European Country for Disease Prevention and Control between the 1 December 2018 and 30 November 2019. In November, Romania and France counted the highest number of cases, with 79 and 48 respectively [13].

In Italy from 1 January 2019 to 31 October 2019, 1605 cases of measles and 19 cases of rubella were reported [14]. The number of measles cases decreased compared to the previous year, in fact outbreaks were reported in 2017 and 2018. In fact, from the 1st of January to the 30th November 2018, 2427 cases of measles were notified [15] and during 2017 (between 1 January and 10 December) 4885 cases of measles were notified in Italy [16].

Individuals at the highest risk for MMRV infections include unvaccinated or inadequately vaccinated persons. The control of MMRV is ensured when reaching the threshold of herd immunity (95% of vaccination coverage with 2 doses) [17]. For that reason, vaccination is important for the general population of adults and children, including IAC.

Further data on the potential clinical and economic impact of different protocols for MMRV vaccination are needed in order to establish the optimal immunization strategy in IAC.

The aim of this study is to evaluate the clinical and economic impact of different protocols of MMRV immunization of IAC. Developing a mathematical model, we compared three possible strategies in order to identify the most advantageous one and optimize MMRV vaccination protocol.

2. Materials and Methods

2.1. Study Design

Features of IAC visiting the Meyer Children’s University Hospital, Florence (Italy), in the period 2009–2018 were included in the mathematical model.
For each child included in the study, the following information was collected and entered in an electronic database, as previously described [1,2]. Briefly, the following information was retrieved for the purpose of the present study: country of origin, gender, age at first observation, vaccine documentation for MMRV, results of serological tests for measles, mumps, rubella, and varicella. At the first evaluation, all the children underwent a venepuncture and laboratory assessment including serologic tests.

All the other laboratory examinations were performed in the same laboratory at the Meyer Children’s University Hospital, using standardized techniques and according to manufacturers’ instructions.

2.2. Decision Analysis Model

The decision analysis model compared the strategy of vaccination based on documentation data versus presumptive vaccination or versus vaccination based on serotesting (Figure 1).

Immunization based on data reported in the vaccination documentation has been chosen as a comparator, since this is the one currently recommended by the Italian Ministry of Health. Therefore, this strategy was compared with: the strategy of pre-vaccination serotesting to all IAC, then, vaccinating only some children based on serological results; the strategy of presumptive vaccination of all IAC without performing serology tests. The model is referred to a hypothetical population of 1000 IAC per year.

![Decision Analysis Model](image)

**Figure 1.** Decision analysis model comparing the strategy of vaccination based on documentation data against pre-vaccination serotesting or compared with presumptive vaccination with no testing. (*protected and unprotected IAC were calculated based on the compliance to the vaccination and the antibody response rate)*.

Vaccination strategy based on documentation records (comparator) considers only reliable immunization documentation, and vaccination is performed in order to complete the immunization schedule appropriate for the age of the children. IAC with no dose recorded should receive two doses of vaccine. IAC who had already received one dose, should receive one additional dose of vaccine.
The protected and unprotected IAC were calculated based on the assumed vaccination coverage and the vaccine antibody response rate. Finally, IAC who received two doses of vaccine in the country of origin, shouldn't receive any dose, but IAC can be categorized as protected and unprotected based on serological test results.

With regard to the pre-vaccination serology strategy (strategy 1), all IAC undergo a serology test for measles, mumps, rubella, and varicella. Therefore, based on sensitivity and specificity of the tests, IAC were classified as true positive, false positive, true negative and false negative. Children with negative results will receive the vaccination. Considering the true negative children, the protected and unprotected IAC were calculated based on the assumed vaccination compliance and the vaccine antibody response rate. Indeed, a proportion of the true negative IAC, despite immunization, will remain unprotected. False negative IAC are already protected and receiving the immunization will receive a booster effect. IAC with true positive and false positive results will not receive any vaccination, and while true positive IAC are indeed protected, false positive IAC not receiving any vaccinations, will remain unprotected.

In presumptive immunization of all IAC (strategy 2), all IAC should receive 2 doses of MMRV vaccine. Based on the assumed immunization coverage, all IAC will receive the first dose, while a small proportion of them will not return for the second dose. Thus, based on the vaccination coverage and the vaccine antibody response rate assumed, a number of children will be protected, while some others will not. Even performing the second dose, a percentage of unprotected children will persist.

In all three strategies vaccination is always hypothesized using the quadrivalent MMRV vaccine. Therefore, for each strategy, based on the decision’s flow chart described above (Figure 1), IAC can be divided into protected (seropositive) and unprotected (seronegative). In fact, even if it seems that high levels of circulating antibodies are important for protection against outbreaks, current data do not give conclusive evidence as to what level of antibodies should be considered protective for each of the VPDs considered, IAC were defined protected when positivity of antibodies levels were serologically determinated and unprotected when negativity of antibodies levels were serologically determinated.

Finally, avoided cases, defined as cases of illness that would have occurred if these children had not been vaccinated, are calculated multiplying the incidence rate for each disease for the number of protected cases. Moreover, possible cases of disease can be estimated by applying the incidence rate for each disease to the not protected cases.

2.3. Population Data

The population data used in the mathematical model are derived from those of 1,927 IAC referred to the Meyer Children’s University Hospital and published in 2020 [18]. The age-group distribution and features of this population were reported to be a hypothetical population of 1000 IAC (Table 1) based on a mathematical proportion.

Table 1. Study population according to age-groups and vaccine preventable disease reported to a population of 1000 internationally adopted children (IAC) per year.

| Age Groups | Measles | Mumps | Rubella | Varicella | Source |
|------------|---------|-------|---------|-----------|--------|
| <1 y       | 26      | 4     | 27      | 17        | Meyer Hospital population reported to 1000 international adopted children per year (2009–2018) |
| 1–4 y      | 391     | 373   | 390     | 338       |        |
| 5–9 y      | 473     | 525   | 474     | 485       |        |
| 10–14 y    | 96      | 94    | 95      | 124       |        |
| 15–18 y    | 14      | 5     | 14      | 36        |        |
| TOTAL      | 1000    | 1000  | 1000    | 1000      |        |

Table 2 shows the incidence of measles, mumps, rubella and varicella for each age group (< 1 y, 1–4 y, 5–9 y, 10–14 y, 15–18 y) included in the model. The reported data is the average of the incidences in the period 2009-2018, and were obtained from the Tuscany Regional Health Agency (ARS) [13].
Table 2. Measles, mumps, rubella and varicella incidences per 100,000 population per year according to age-groups (2009–2018) [19].

| Age Groups | Measles | Mumps | Rubella | Varicella |
|------------|---------|-------|---------|-----------|
| <1 y       | 15.2    | 1.6   | 0.3     | 275.3     |
| 1–4 y      | 7.3     | 10.0  | 0.9     | 547.4     |
| 5–9 y      | 3.5     | 6.3   | 0.3     | 369.8     |
| 10–14 y    | 2.6     | 3.1   | 0.2     | 88.9      |
| 15–18 y    | 4.4     | 1.2   | 0.5     | 22.6      |

Vaccine documentation was assessed considering the number of doses recorded for MMRV.

With regards to seroprevalence of antibody protection against MMRV, children were subdivided according to age in five groups (< 1 y, 1–4 y, 5–9 y, 10–14 y, 15–18 y) and classified as protected or unprotected against each specific VPD on the basis of serotesting results.

2.4. Vaccine Probabilities and Cost Estimates

Since IAC have been reported to display a high coverage rate for vaccines [11], we assumed that 100% of IAC would receive the first MMRV dose, while 95% of IAC would complete the 2 dose series.

Vaccine MMRV antibody response was obtained from published data by the CDC [20–23] and was considered to be 98% for measles, 78% for mumps, 95% for rubella, and 65% for varicella for one dose; 99% for measles, 88% for mumps, 99% for rubella, and 95% for varicella for two doses.

Charges for serotesting (including cost of blood draw, antibody determination, laboratory technicians) were obtained from the price offered to the Meyer Hospital and the Department of Health Science, University of Florence, Florence (Italy). The analysis was developed applying the enzyme-linked immunosorbent assay (ELISA). Costs of the serology tests were calculated to be 6.28 Euro for measles per child, 5.86 Euro for mumps per child, 5.86 Euro for rubella per child, and 6.28 Euro for varicella per child (Table 3).

The cost of the laboratory technician for each serology performed was calculated as follows. The hourly salary for a laboratory technician, which is 18.50 Euro, was multiplied by the number of hours necessary to set up the serology kit. The time required is on average six hours, during which the technician is engaged in selecting the sample, doing the dilution and analysing the results. The total is finally divided for the number of wells in the serological kit, that in our case is 46. In fact, in a 96-well plate, four wells were the control (positives and negatives) and the remaining wells, made of 46 reactive wells and 46 non-reactive wells, were used to perform the sample serology. This means that each serology sample had to be performed twice.

Therefore, the cost of the laboratory technician for each well was calculated to be: 18.50 (Euro) × 6 (hours)/46 (wells) = 2.41 (Euro).

The charge for blood draw for the serology was considered to be 4.00 Euro.

The cost of vaccine was calculated including the charge of administering single immunization (5.91 Euro) (based on previously published Italian studies by Gasparini et al. and Di Pietro et al.) [24,25] and the cost of MMRV vaccine (obtained by the Tuscany Regional Healthy Agency). Two MMRV vaccines have been used during the study period and costs change over years, therefore the weighted average cost was calculated to be 46.30 Euro (Table 4).

Table 3. Cost estimates.

| Costs                                | Base Cost Estimate, Euro | Sources                      |
|--------------------------------------|--------------------------|------------------------------|
| Cost of vaccine                      | 46.30                    | Tuscany Regional Healthy Agency |
| Charge for administering immunization | 5.91                     | [24,25]                      |
| Charge for blood draw for serology    | 4.00                     | Price                        |
Cost of serology kit | ELISA | CLIA |
|-------------------|-------|------|
| Measles           | 6.28  | 2.45 |
| Mumps             | 5.86  | 2.45 |
| Rubella           | 5.86  | 1.57 |
| Varicella         | 6.28  | 1.96 |

| Charge for the laboratory technician per serology test | 2.41 |
|-------------------------------------------------------|-----|

In the analysis of each VPD, the cost of the vaccine was divided into the four parts of the MMRV vaccine. Even the cost of the blood draw was divided for four parts, as a single blood draw is enough to perform the four serologies.

2.5. Sensitivity and Specificity of Serology Tests

Sensitivity and specificity of specific ELISA for MMRV are reported in Table 4. Since, additional serological methods are available, in the study further analyses were executed performing chemiluminescent immunoassay (CLIA) with sensitivity, specificity and costs reported in Table 4. Lastly, the costs of serologic tests are summarized in Table 3.

**Table 4. Sensitivity and specificity of the serology tests.**

| Methods | Measles | Mumps | Rubella | Varicella |
|---------|---------|-------|---------|-----------|
| ELISA   | Sensitivity | 0.996 | 0.954 | 1 | 0.993 |
|         | Specificity | 1     | 0.937 | 0.985 | 1 |
| CLIA    | Sensitivity | 0.974 | 0.985 | 0.995 | 1 |
|         | Specificity | 1     | 0.985 | 0.996 | 0.971 |

Note: Information provided by the manufacturers.

In addition, as MMRV vaccine is performed after the first year of life, the analysis has been repeated excluding IAC <1 year of age.

2.6. Strategy Cost Estimates

The costs for each strategy were calculated for a population of 1000 IAC. The number of protected and unprotected IAC were used to calculate the number of avoided cases and the number of possible cases for each single disease and for all 4 VPDs together. This allows to directly compare the costs and the benefits of the strategies.

Moreover, the comparator strategy was matched to the other two strategies by calculating the incremental cost-effectiveness ratio for protected children (ICER = costs difference / benefits difference).

2.7. Ethical Approval and Informed Consent

The study received approval by Meyer University Hospital Ethics Committee, the Ethical Code Number is 15/2010.

Parents who consented to their adoptive children participating in the study have signed a written informed consent.

3. Results

Vaccine documentation was assessed considering the number of doses recorded for MMRV. This data referred to the Meyer Children’s University Hospital and reported to a population of 1,000 IAC, as entered in Table 5. To apply strategy 1, the number of vaccine doses needed to be administered was calculated based on this data.

**Table 5. Documentation of vaccination for the IAC enrolled from the Meyer Children’s University Hospital and referred to a hypothetical population of 1000 IAC.**
On the basis of serotesting results, children were subdivided according to age in five groups and classified as protected or unprotected against each specific VPD as entered in Table 6.

Table 6. Seroprevalence of the internationally adopted children (IAC) enrolled at the Meyer Children’s University Hospital and referred to a hypothetical population of 1,000 IAC.

| VPD    | Measles | Mumps | Rubella | Varicella |
|--------|---------|-------|---------|-----------|
|        | negativ | positiv | negativ | positiv | negativ | positiv | negativ | positiv |
| Seroprevalence of IAC by age | es | es | es | es | es | es | es | es |
| < 1 y  | 23 | 3 | 120 | 0 | 22 | 5 | 13 | 5 |
| 1–4 y  | 140 | 251 | 160 | 200 | 137 | 253 | 231 | 106 |
| 5–9 y  | 149 | 325 | 120 | 360 | 127 | 346 | 185 | 300 |
| 10–14 y | 32 | 64 | 0 | 40 | 33 | 62 | 21 | 103 |
| 15–18 y | 8 | 6 | 0 | 0 | 2 | 12 | 10 | 27 |

Compared with the immunization based on documentation strategy (comparator), presumptive immunization (strategy 2) for measles increases the cost per strategy from 17,445.68 Euro to 25,452.38 Euro. The number of protected IAC rises from 961 to 990; therefore, the cost per protected child increases from 18.16 Euro to 25.72 Euro. However, comparing the pre-vaccination serotesting strategies (strategy 1) with the comparator for measles, the cost per strategy increases less (from 17,445.68 Euro to 18,635.40 Euro), while the number of protected IAC increases more markedly from 961 to 994; therefore, the cost per protected child increases from 18.16 Euro to 18.75 Euro (Table 7). Therefore, as far as measles is concerned, the comparator is less expensive, but strategy 1 is more effective for number of protected IAC.

In fact, the ICER, defined above as the difference between the costs and the difference between the benefits (as number of protected IAC), was calculated comparing strategy 2 and strategy 1 with the comparator. By vaccinating all IAC, the ICER would be 279.28 Euro per protected child, when compared to the comparator. Indeed, comparing the strategy 1 vs the comparator, the ICER is 36.18 Euro per protected child (Table 8). This means that although the serology strategy is slightly more expensive, it is the most effective approach compared to the comparator and more advantageous compared to strategy 2.

Comparing strategy 2 with the comparator for mumps, the cost per strategy increases from 9,482.39 Euro to 25,452.38 Euro, whereas the number of protected IAC decreases from 915 to 875. The
The cost per protected child increases from 10.36 Euro to 29.09 Euro. Comparing strategy 1 with the comparator, the cost per strategy increases from 9,482.39 to 19,453.99, while the number of protected IAC increases from 915 to 926. The cost per protected child increases from 10.36 Euro to 21.02 Euro, (Table 7). Therefore, the presumptive immunization strategy is dominated (more expensive and less effective) by comparator, while comparing strategy 1 to the comparator, the ICER is 944.77 Euro per protected child (Table 8).

Comparing strategy 1 with the comparator for rubella and varicella the cost of the strategies decreases from 18,245.20 Euro to 17,461.95 Euro and from 23,945.44 Euro to 21,390.65 Euro, respectively. Conversely, the number of protected IAC increases from 962 to 998 for rubella and from 930 to 966 for varicella. The cost per child protected decreases from 18.95 Euro to 17.49 Euro and from 25.74 Euro to 22.14 Euro, respectively. Therefore, the comparator is dominated by strategy 1 (less expensive and more effective). Moreover, for both VPDs, vaccination of all IAC is the most expensive strategy (25,452.38 Euro for rubella and for varicella). When compared to the comparator, strategy 2 increases the number of protected IAC from 963 to 995 for rubella and from 930 to 934 for varicella. (Table 7). Comparing strategy 2 to the comparator, the ICER is 222.82 Euro per protected child for rubella and 394.92 Euro per protected child for varicella (Table 8).

Finally, considering all VPDs together, comparing strategy 1 with the comparator, the cost of the strategy increases from 69,118.72 Euro to 76,941.99 Euro and even the number of protected IAC increases from 3769 to 3884. The cost per protected child increases from 18.34 Euro to 19.81 Euro. Comparing strategy 2 with the comparator, the cost of the strategy increases to a greater extent: from 69,118.72 Euro to 101,809.50 Euro and the number of protected IAC increases from 3769 to 3794. The cost per patient increases from 18.34 Euro to 26.84 Euro (Table 7). Therefore, compared to the other strategies, the comparator strategy is less expensive. On the other hand, the pre-vaccination serotesting strategy against MMRV together, improves the number of protected IAC with a minimum increment of costs compared with the immunization based on documentation strategy. Therefore, from a cost-effectiveness point of view, vaccination based on serotesting results in the most advantageous strategy. As a matter of fact, with an expenditure of 7823.28 Euro more than the comparator strategy, strategy 1 is associated with 115 more protected IAC (Table 7 and Table 8).

Performing the analysis using CLIA, pre-vaccination serotesting is overall the most convenient approach (Tables A1-2).

Finally, excluding children aged <1 year, performing both methods of serology (ELISA and CLIA), similar results were obtained (Tables A3-6).

| VPD   | Strategy   | Total Cost of the Strategy (Euro) | IAC 1 Protected (N) | Avoided Cases (N) | Possible Cases (N) | Cost Per Protected Children (Euro) |
|-------|------------|----------------------------------|---------------------|-------------------|-------------------|-----------------------------------|
| Measles | Comparator | 17,445.68                          | 960.83              | 0.0501            | 0.0018            | 18.16                             |
|        | Strategy 1 | 18,635.40                          | 993.72              | 0.0516            | 0.0003            | 18.75                             |
|        | Strategy 2 | 25,452.38                          | 989.50              | 0.0514            | 0.0005            | 25.72                             |
| Rubella | Comparator | 18,245.20                          | 962.78              | 0.00507           | 0.00013           | 18.95                             |
|        | Strategy 1 | 17,461.95                          | 998.46              | 0.00520           | 0.00001           | 17.49                             |
|        | Strategy 2 | 25,452.38                          | 995.13              | 0.00518           | 0.00003           | 25.58                             |
| Mumps  | Comparator | 9,482.39                           | 915.02              | 0.0664            | 0.0067            | 10.36                             |
|        | Strategy 1 | 19,453.99                          | 925.55              | 0.0641            | 0.0050            | 21.02                             |
|        | Strategy 2 | 25,452.38                          | 875.00              | 0.0639            | 0.0091            | 29.09                             |
| Varicella | Comparator | 23,945.44                          | 930.43              | 3.5382            | 0.2688            | 25.74                             |
|        | Strategy 1 | 21,390.65                          | 966.00              | 3.6623            | 0.1446            | 22.14                             |
|        | Strategy 2 | 25,452.38                          | 934.25              | 3.5566            | 0.2503            | 27.24                             |
| All VPDs together | Comparator | 69,118.72                          | 3,769.06            | 3.6598            | 0.28              | 18.34                             |
|        | Strategy 1 | 76,941.99                          | 3,883.72            | 3.7832            | 0.15              | 19.81                             |
|        | Strategy 2 | 101,809.50                         | 3,793.88            | 3.6771            | 0.26              | 26.84                             |
Note: IAC = Internationally adopted children; comparator = vaccine based on vaccination records; strategy 1 = vaccine based on serology; strategy 2 = vaccine to all IAC.

Table 8. Comparison of strategies according to disease (ELISA method).

| VPD   | Comparison of Strategies vs Comparator | Difference of Costs (Euro Per 1,000 Children) | Difference in Protected Children (N Per 1,000) | ICER (Euro Per Protected Case) |
|-------|----------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------|
| Measles | Serology                               | 1,189.72                                      | 32.89                                         | 36.18                          |
|        | Presumptive immunization               | -783.25                                       | 35.68                                         | Dominant                       |
| Rubella | Serology                               | 7,207.17                                      | 32.35                                         | 222.82                         |
|        | Presumptive immunization               | 9,971.60                                      | 10.53                                         | 946.77                         |
| Mumps  | Presumptive immunization               | 15,969.98                                     | -40.02                                        | Dominated                      |
| Varicella | Serology                               | -2,554.79                                     | 35.56                                         | Dominant                       |
|        | Presumptive immunization               | 1,506.93                                      | 3.82                                          | 394.92                         |
| All VPDs together | Serology                               | 7,823.28                                      | 114.66                                        | 68.23                          |
|        | Presumptive immunization               | 32,690.78                                     | 24.81                                         | 1,317.51                       |

Note: Presumptive immunization of all internationally adopted children; comparator vaccinations of international adopted children according to their documentation of previous vaccinations; Serology = vaccinations of international adopted children according to serotesting results.

4. Discussion and conclusion

Considering MMRV, pre-vaccination serotesting compared to immunization based on documentation in IAC improves outcomes with a minimal cost increase, while the presumptive immunization strategy is the most expensive and it is associated with a number of protected children lower than pre-vaccination serotesting.

Although immunization based on documentation is the strategy currently recommended in Italy [26], in our analysis, the cost-saving of this strategy was minimal compared to the benefits of serotesting strategy, performing ELISA serology. On the other hand, all the other outcomes (total number of protected IAC, number of possible cases, and number of avoided cases) were greater than the pre-immunization serotesting approach. However, performing CLIA serologies, clinical and economic outcomes were more advantageous by applying the pre-vaccination serotesting strategy. In fact, in this case, pre-vaccination serotesting compared to the comparator decreases the costs, increases the percentage of protected IAC against all four VPDs, increases the number of avoided cases and decreases the number of possible cases.

There is no standard criteria for measuring cost-effectiveness in vaccination strategies for IAC [11]. To our knowledge, this is the first clinical and economic analysis of the MMRV vaccine in IAC. Only Cohen et al. in 2006 conducted an economic analysis of pre-vaccination serotesting compared with presumptive immunization for poliomyelitis, diphtheria, and tetanus in IAC and immigrant children. This study demonstrated that the pre-vaccination serotesting for poliomyelitis increases the cost and decreases the percentage of patients protected [11]. Another study targeting child refugees analysed the most convenient strategy comparing pre-vaccination serotesting with presumptive immunization for varicella and concluded that pre-vaccination serotesting is cost-effective in children <5 years of age [8]. Other similar studies are available for hepatitis B and hepatitis A, but these refer to a population of native children [9], [10].

Therefore, due to the shortage of published data, our study highlights the necessity of further studies investigating the most cost-effective immunization strategy that targets IAC.
Our study has several potential limitations. Firstly, the costs in our study are derived from the University of Florence (Health Science Department, Meyer Children Hospital) and may not reflect costs at other institutions. Secondly, no study investigated the coverage rates for the immunization in IAC, so we relied on expert opinions to evaluate the reported rates. Thirdly, a limited number of IAC underwent mumps serology testing in the Meyer Hospital population. Fourthly, in-directed costs (i.e., wages lost by caregivers) were not considered. Moreover, considering the strategy of the presumptive immunization of all IAC, the additional costs of potential side effects of unnecessary vaccination in protected children were not considered. However, severe adverse events are extremely rare, and we speculate that our results are not or are minimally affected by this omission. Lastly, there is no absolute association between being unprotected (seronegative) and not having protective antibody titers, since immune response to vaccines is complex and relies on different immunologic mechanisms which are not all explored by serology testing [27]. In fact, current data does not give conclusive evidence what level of antibodies should be considered protective for MMRV, even if it seems that high levels of circulating antibodies are important in protection against outbreaks [28–30]. Moreover, our analysis is based on several assumptions. Firstly, the vaccine selected is against MMRV, due to the fact that the monovalent vaccines are not used in medical practice in Italy. Secondly, the coverage rate was assumed to be 100% for the first dose of MMRV vaccine and 95% for the second dose. Indeed, adoptive parents are generally very attentive to their children's medical needs and IAC are usually well integrated into the national health system. Moreover, in Tuscany (Italy), a first screening evaluation for newly arrived IAC is free of charge and a first blood draw is already performed in all IAC as a general assessment. Therefore, the costs for the serology could decrease, not considering the cost for the venepuncture. Finally, this model was developed by modifying input data of the methods used to perform the serology for measles, mumps, rubella and varicella (ELISA and CLIA). CLIA is the method currently used at the Anna Meyer Hospital of Florence. Varying the method for the serology tests, the sensitivity, specificity and costs, change. The obtained results are almost comparable to the results described above, except for the costs, and indeed in this case pre-vaccination serotesting is also the cost-saving strategy compared with the others. Similar results were obtained excluding children aged < 1 year.

Further studies are needed to assess the coverage rate of IAC to the immunization protocols. Moreover, it could be interesting to extend this analysis to the entire immigrant population. Probably the relation between documentation and serology could differ from IAC, and the assumed coverage rate could be lower.

In conclusion, based on our analyses, considering MMRV vaccine, serotesting strategy appears to be the preferred option in IAC. However, results of this study refer to a particular kind of population: IAC often arrive to the new country with unknown or unreliable vaccination documentation. Moreover, IAC are subjected to numerous routine examinations promptly after their arrival that can be integrated with the MMRV serology. Therefore, the results of this study that highlight the importance of pre-vaccination serotesting can be applied only in IAC and cannot be extended to the general population.

Author Contributions: Conceptualization, E.C., A.B., S.B.; Data curation: C.M.A., A.B. and S.B.; Formal Analysis: A.B. and S.B.; validation, S.B, P.B, L.G. and E.C.; investigation, C.M.A.; resources, E.C. and L.G.; data curation, C.M.A.; writing—original draft preparation: C.M.A.; writing—review and editing: all authors; visualization: C.M.A., L.G. and S.B; supervision, L.G, S.B, P.B.; project administration, E.C.; funding acquisition, S.B, A.B., E.C. and L.G.” All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially supported by the Ente Cassa di Risparmio di Firenze funded by Cassa di Risparmio, grant number 24151.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix
Table A1. Clinical and economic outcomes per 1,000 internationally adopted children (IAC), by disease (CLIA serotesting).

| VPD     | Strategy            | Total Cost of The Strategy (Euro) | IAC Protected (N) | Avoided Cases (N) | Possible Cases (N) | Cost Per Child Protected (Euro) |
|---------|---------------------|-----------------------------------|-------------------|------------------|--------------------|----------------------------------|
| Measles | Comparator          | 17,445.68                         | 960.83            | 0.0501           | 0.0018             | 18.16                           |
|         | Strategy 1          | 14,906.42                         | 979.45            | 0.0509           | 0.0010             | 15.22                           |
|         | Strategy 2          | 25,452.38                         | 989.50            | 0.0514           | 0.0005             | 25.72                           |
| Rubella | Comparator          | 18,245.20                         | 962.78            | 0.00507          | 0.00013            | 18.95                           |
|         | Strategy 1          | 13,234.60                         | 995.05            | 0.00518          | 0.00030            | 13.30                           |
|         | Strategy 2          | 25,452.38                         | 995.13            | 0.00518          | 0.00030            | 25.58                           |
| Mumps   | Comparator          | 9,482.39                          | 915.02            | 0.0664           | 0.0067             | 10.36                           |
|         | Strategy 1          | 16,145.01                         | 941.90            | 0.0653           | 0.0038             | 17.14                           |
|         | Strategy 2          | 25,452.38                         | 875.00            | 0.0639           | 0.0091             | 29.09                           |
| Varicella | Comparator        | 23,945.44                         | 930.43            | 3.5382           | 0.2688             | 25.74                           |
|         | Strategy 1          | 17,151.46                         | 970.66            | 3.6788           | 0.1282             | 17.67                           |
|         | Strategy 2          | 25,452.38                         | 934.25            | 3.5566           | 0.2503             | 27.24                           |
| All VPDs together | Comparator       | 69,118.72                         | 3,769.06          | 3.6598           | 0.2773             | 18.34                           |
|         | Strategy 1          | 61,437.50                         | 3,887.05          | 3.8002           | 0.1330             | 15.81                           |
|         | Strategy 2          | 25,452.38                         | 875.00            | 3.6771           | 0.2600             | 26.84                           |

Note: IAC = Internationally adopted children; comparator = vaccine based on vaccination records; strategy 1 = vaccine based on serology; strategy 2 = vaccine to all IAC; VPDs = vaccine preventable diseases; CLIA = chemiluminescent immunoassay.

Table A2. Comparison of strategies according to different VPDs (CLIA method).

| VPD     | Comparison of Strategies vs Comparator | Difference of Costs (Euro Per 1,000 Children) | Difference in Protected Children (N Per 1,000) | ICER (Euro Per Protected Case) |
|---------|---------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------|
| Measles | Serology                              | -2,539.26                                     | 18.61                                         | Dominant                       |
|         | Presumptive immunization               | 8,006.70                                      | 28.67                                         |                                |
| Rubella | Serology                              | -5,010.60                                     | 32.27                                         | Dominant                       |
|         | Presumptive immunization               | 7,207.17                                      | 32.35                                         |                                |
| Mumps   | Serology                              | 6,662.62                                      | 26.88                                         | 247.84                         |
|         | Presumptive immunization               | 15,969.98                                     | -40.02                                        | Dominated                      |
| Varicella | Serology                           | -6,793.98                                     | 40.22                                         | Dominant                       |
|         | Presumptive immunization               | 1,506.93                                      | 3.82                                          |                                |
| All VPDs together | Serology                 | -7,681.21                                     | 117.99                                        | Dominant                       |
|         | Presumptive immunization               | 32,690.78                                     | 24.81                                         | 1,317.51                       |

IAC = internationally adopted children; VPD = vaccine preventable disease; Presumptive immunization of all international adopted children; comparator = vaccinations of internationally adopted children according to their documentation of previous vaccinations; Serology = vaccinations of internationally adopted children according to serotesting results; CLIA = chemiluminescent immunoassay.

Table A3. Clinical and economic outcomes per 1,000 internationally adopted children (IAC) excluding children <1 year of age (ELISA serotesting).

| VPD     | Strategy | Total Cost of The Strategy (Euro) | IAC Protected (N) | Avoided Cases (N) | Possible Cases (N) | Cost Per Child Protected (Euro) |
|---------|----------|-----------------------------------|-------------------|------------------|--------------------|----------------------------------|
| Measles | Comparator          | 17,445.68                         | 960.83            | 0.0501           | 0.0018             | 18.16                           |
|         | Strategy 1          | 14,906.42                         | 979.45            | 0.0509           | 0.0010             | 15.22                           |
|         | Strategy 2          | 25,452.38                         | 989.50            | 0.0514           | 0.0005             | 25.72                           |
| Rubella | Comparator          | 18,245.20                         | 962.78            | 0.00507          | 0.00013            | 18.95                           |
|         | Strategy 1          | 13,234.60                         | 995.05            | 0.00518          | 0.00030            | 13.30                           |
|         | Strategy 2          | 25,452.38                         | 995.13            | 0.00518          | 0.00030            | 25.58                           |
| Mumps   | Comparator          | 9,482.39                          | 915.02            | 0.0664           | 0.0067             | 10.36                           |
|         | Strategy 1          | 16,145.01                         | 941.90            | 0.0653           | 0.0038             | 17.14                           |
|         | Strategy 2          | 25,452.38                         | 875.00            | 0.0639           | 0.0091             | 29.09                           |
| Varicella | Comparator        | 23,945.44                         | 930.43            | 3.5382           | 0.2688             | 25.74                           |
|         | Strategy 1          | 17,151.46                         | 970.66            | 3.6788           | 0.1282             | 17.67                           |
|         | Strategy 2          | 25,452.38                         | 934.25            | 3.5566           | 0.2503             | 27.24                           |
| All VPDs together | Comparator       | 69,118.72                         | 3,769.06          | 3.6598           | 0.2773             | 18.34                           |
|         | Strategy 1          | 61,437.50                         | 3,887.05          | 3.8002           | 0.1330             | 15.81                           |
|         | Strategy 2          | 25,452.38                         | 875.00            | 3.6771           | 0.2600             | 26.84                           |
| Strategy | Comparator | Strategy 1 | Strategy 2 |
|----------|------------|------------|------------|
| Measles  | 17,257.47  | 18,275.01  | 25,452.38  |
|          | 960.06     | 993.81     | 989.50     |
|          | 0.0474     | 0.0489     | 0.0487     |
|          | 0.0018     | 0.0003     | 0.0005     |
|          | 17.98      | 18.39      | 25.72      |
| Rubella  | 18,049.73  | 17,103.47  | 25,452.38  |
|          | 961.87     | 998.52     | 995.13     |
|          | 0.00512    | 0.00525    | 0.00523    |
|          | 0.00014    | 0.00001    | 0.00003    |
|          | 17.13      | 18.39      | 25.72      |
| Mumps    | 9,425.43   | 17,371.53  | 25,452.38  |
|          | 915.16     | 931.37     | 875.00     |
|          | 0.0666     | 0.0709     | 0.0641     |
|          | 0.0067     | 0.0054     | 0.0092     |
|          | 10.30      | 18.65      | 29.09      |
| Varicella| 23,918.71  | 21,269.77  | 25,452.38  |
|          | 930.37     | 966.28     | 934.25     |
|          | 3.5553     | 3.6809     | 3.5741     |
|          | 0.2703     | 0.1447     | 0.2515     |
|          | 25.71      | 22.01      | 27.24      |
| All VPDs together | Comparator | 68,651.33 | 74,019.77 |
|          | 3,767.46 | 3,889.98 | 3,692.1 |
|          | 3.6744 | 3.8060 | 3.6921 |
|          | 0.2789 | 0.1504 | 0.2612 |
|          | 18.22 | 19.03 | 26.84 |

Note: IAC = internationally adopted children; comparator = vaccine based on vaccination records; strategy 1 = vaccine based on serology; strategy 2 = vaccine to all IAC; VPDs = vaccine preventable diseases; ELISA = enzyme-linked immunosorbent assay.

Table A4. Comparison of strategies according to different VPDs excluding children <1 year of age (ELISA method).

| VPD | Comparison of Strategies vs Comparator | Difference of Costs (Euro Per 1,000 Children) | Difference in Protected Children (N Per 1,000) | ICER (Euro Per Protected Case) |
|-----|----------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------|
| Measles | Serology | 1,017.54 | 33.75 | 30.15 |
|        | Presumptive immunization | 8,194.91 | 29.44 | 278.35 |
| Rubella | Serology | -946.27 | 36.65 | Dominant |
|        | Presumptive immunization | 7,402.64 | 33.25 | 222.60 |
| Mumps | Serology | 7,946.10 | 16.21 | 490.23 |
|        | Presumptive immunization | 16,026.95 | -40.16 | Dominated |
| Varicella | Serology | -2648.94 | 35.91 | Dominant |
|        | Presumptive immunization | 1,533.67 | 3.88 | 394.92 |
| All VPDs together | Serology | 5,368.44 | 122.52 | 43.82 |

IAC = internationally adopted children; VPD vaccine preventable disease; Presumptive immunization of all international adopted children; Vax-Doc = vaccinations of international adopted children according to their documentation of previous vaccinations; Serology = vaccinations of international adopted children according to serotesting results.

Table A5. Clinical and economic outcomes per 1,000 internationally adopted children (IAC) < 1 year of age (CLIA method).


| VPD          | Comparator       | Strategy 1       | Strategy 2       | Difference of Cost (Euro Per 1,000 Children) | Difference in Protected Children (N Per 1,000) | ICER (Euro Per protected Case) |
|--------------|------------------|------------------|------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------|
| Measles      | Serology         | 12,876.12        | 995.04           | 0.00523                                       | 0.00003                                       | 12.94                         |
|              | Presumptive      | 25,452.38        | 995.13           | 0.00523                                       | 0.00003                                       | 25.58                         |
| Rubella      | Serology         | 9,425.43         | 915.16           | 0.0666                                        | 0.0067                                        | 10.30                         |
|              | Presumptive      | 14,062.55        | 950.72           | 0.0723                                        | 0.0040                                        | 14.79                         |
| Mumps        | Serology         | 25,452.38        | 875.00           | 0.0641                                        | 0.0092                                        | 29.09                         |
| Varicella    | Serology         | 23,918.71        | 930.37           | 3.5553                                        | 0.0666                                        | 27.24                         |
|              | Presumptive      | 14,062.55        | 950.72           | 0.0723                                        | 0.0040                                        | 14.79                         |
|              |                   | 25,452.38        | 875.00           | 0.0641                                        | 0.0092                                        | 29.09                         |
| All VPDs     | Serology         | 68,651.33        | 3,767.46         | 3.6744                                        | 0.2789                                        | Dominant                      |
|              | Presumptive      | 58,515.28        | 3,895.95         | 3.8232                                        | 0.1332                                        | 15.02                         |
|              |                   | 101,809.50       | 3,793.88         | 3.5741                                        | 0.2515                                        | 27.24                         |

Note: IAC = Internationally adopted children; comparator = vaccine based on vaccination records; strategy 1 = vaccine based on serology; strategy 2 = vaccine to all IAC; VPDs = vaccine preventable diseases; CLIA = chemiluminescent immunoassay.

Table A6. Comparison of strategies according to different VPDs excluding children <1 year of age (CLIA method).

References

1. Sollai, S.; Ghetti, F.; Bianchi, L.; De Martino, M.; Galli, L.; Chiappini, E. Infectious diseases prevalence, vaccination coverage, and diagnostic challenges in a population of internationally adopted children referred to a Tertiary Care Children’s Hospital from 2009 to 2015. *Medicine* 2017, *96*, 1–10.
2. Chiappini, E.; Zaffaroni, M.; Bianconi, M.; Veneruso, G.; Grasso, N.; Garazzino, S.; Bona, G. Italian multicentre study found infectious and vaccine-preventable diseases in children adopted from Africa and recommends prompt medical screening. *Paediatr.* 2018, *107*, 1581–1586.
3. Pickering, L. K.; Baker, C. J.; Freed, G. L.; Gall, S. A.; Grogg, S. E.; Poland, G. A.; Orenstein, W. A. Immunization Programs for Infants, Children, Adolescents, and Adults: Clinical Practice Guidelines by the Infectious Diseases Society of America. *CID.* 2009, *49*, 817–838. https://doi.org/10.1086/605430.
4. Centers for Disease Control and Prevention. International adoption. Available online: https://wwwnc.cdc.gov/travel/yellowbook/2020/family-travel/international-adoption (accessed on 8 September 2019).
5. Jones, V. F.; Schulte, E. E. Comprehensive Health Evaluation of the Newly Adopted Child. *Pediatrics.* 2019, *143*, 6–57.
6. Jones, V. Committee on Early Childhood, Adoption, and Dependent Care. Comprehensive health evaluation of the newly adopted child. *Pediatrics*. 2012, 129, 214–223.

7. Schulte, J.; Maloney, S.; Aronson, J.; Gabriel, P.; Zhou, J.; Saiman, L. Evaluating Acceptability and Completeness of Overseas Immunization Records of Internationally Adopted Children. *Pediatrics*. 2002, 109, 2–5.

8. Figueira, M.; Christiansen, D.; Barnett, ED. Cost-effectiveness of serotyping compared with universal immunization for varicella in refugee children from six geographic regions. *J Travel Med.* 2003, 10, 203–207.

9. Kwan-Gett, T.; Whitaker, R.; Kemper, K. A cost-effectiveness analysis of prevaccination testing for hepatitis B in adolescents and preadolescents. *Arch Pediatr Adolesc Med.* 1994, 148, 915–920.

10. Plans Rubio, P. Critical value of prevalence for vaccination programmes. The case of hepatitis A vaccination in Spain. *Vaccine*. 1997, 15, 1445–1450.

11. Cohen, A. L.; Veenstra, D. Economic Analysis of Prevaccination Serotyping Compared With Presumptive Immunization for Polio, Diphtheria and Tetanus in Internationally Adopted. *Pediatrics*. 2006, 117, 1650–1655.

12. European Centre for Disease Prevention and Control. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA. Available online: https://www.ecdc.europa.eu/sites/portal/files/documents/Public health guidance on screening and vaccination of migrants in the EU EEA.pdf. (Accessed on 01 August 2019).

13. European Centre for Disease Prevention and Control. Monthly measles and rubella monitoring report January 2020. Available online: https://www.ecdc.europa.eu/en/publications-data/monthly-measles-and-rubella-monitoring-report-january-2020 (accessed on 27 January 2020)

14. Istituto Superiore di Sanità. Il portale dell’epidemiologia per la sanità pubblica a cura dell’Istituto superiore di sanità. Ultimi aggiornamenti. Available online: https://www.epicentro.iss.it/morbilloaggiornamenti (Accessed on 21 January 2020).

15. Epicentro. Morbillo & Rosolia News: il bollettino di dicembre 2018. Available online: https://www.epicentro.iss.it/morbillo/2018 (Accessed on 24 January 2020)

16. Epicentro. Morbillo in Italia: dal bollettino settimanale a quello mensile. Available online: https://www.epicentro.iss.it/morbillo/2017 (Accessed on 24 January 2020).

17. Ministry of Health. National Vaccine Prevention Plan (PNPV) 2017-2019. Available online: https://www.gazzettaufficiale.it/eli/id/2017/02/18/17A01195/sg (Accessed on 3 January 2020).

18. E. Bechini, A.; Boccalini, S.; Alimenti, C.M.; Galli, L.; Chiappini, E. Immunization status against measles, mumps, rubella and varicella in a large population of internationally adopted children referred to Meyer Children University Hospital from 2009 to 2018 *Vaccines J.* 2020. (unpublished)

19. Agenzia Regionale della sanità Toscana. (Italia). *Incidenza morbillo, parotite, rosolia, varicella*. Personal communication, 2019.

20. Centers for Disease Control and Prevention. Measles. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html (accessed on 17 September 2019).

21. Centers for Disease Control and Prevention. Mumps. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/mumps.html (accessed on 17 September 2019).

22. Centers for Disease Control and Prevention. Rubella. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/rubella.html (accessed on 17 September 2019).

23. Centers for Disease Control and Prevention. Varicella. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/varicella.html (accessed on 17 September 2019).

24. Gasparini, R.; Landa, P.; Amicizia, D.; Icardi, G.; Ricciardi, W.; De Waure, C. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis. *Hum. Vaccin. Immunother.* 2016, 12, 2148–2161.

25. Di Pietro, M.; Capri, S.; Kheiraoui, F.; de Waure, C.; Quarta, G.; Poscia, A. Health Technology Assessment della vaccinazione contro Meningococco B. *QJPH.* 2013, 2, 1–113.

26. Società italiana di pediatria. (Roma). Nuove indicazioni del GLNBI-SIP per l’accoglienza sanitaria al minore migrante - Roma 30 novembre 2013. *Consensus Conference GLNBI-SIP.* 2013. Available online: http://www.glnbi.org/documenti ila8a8ee7817af2e8917c913ebe30189.pdf. (accessed on 1 September 2019).

27. S. Wundenberg, T.; van Binnendijk, R.; Veldhuijzen, I.; Woonink, F.; Ruijs, H.; van del Klis, F.; Kerkhof, J.; de Melker, H.; de Swart, R.; Hahné, S. Additional Evidence on serological correlates of protection against
Measles: an observational cohort study among once vaccinated children exposed to measles. *Vaccines (Basel).* 2019, 7, 158.

28. Neumann PW, Weber JM, Jessamine AG, O'Shaughnessy MV. Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status. *J. Clin. Microbiol.* 1985, 22, 296–298.

29. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: reevaluation of protective titers. *J. Infect. Dis.* 1990, 162, 1036–42.

30. Chen X, Bailleux F, Desai K, Qin L, Dunning AJ. A threshold method for immunological correlates of protection. *BMC Med. Res. Methodol.* doi: 10.1186/1471-2288-13-29.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).